{"id":12628,"date":"2026-10-01T18:52:54","date_gmt":"2026-10-01T09:52:54","guid":{"rendered":"https:\/\/kojihifu.com\/english\/?p=12628"},"modified":"2026-10-01T18:52:56","modified_gmt":"2026-10-01T09:52:56","slug":"aga-vs-finasteride-minoxidil-regenerative-tokyo","status":"publish","type":"post","link":"https:\/\/kojihifu.com\/english\/aga-vs-finasteride-minoxidil-regenerative-tokyo\/","title":{"rendered":"AGA vs Finasteride and Minoxidil: Regenerative Tokyo Guide"},"content":{"rendered":"<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"MedicalWebPage\",\"@id\":\"https:\/\/kojihifu.com\/english\/aga-vs-finasteride-minoxidil-regenerative-tokyo\/#webpage\",\"url\":\"https:\/\/kojihifu.com\/english\/aga-vs-finasteride-minoxidil-regenerative-tokyo\/\",\"name\":\"AGA vs Finasteride and Minoxidil: Regenerative Tokyo Guide\",\"inLanguage\":\"en\",\"isPartOf\":{\"@id\":\"https:\/\/kojihifu.com\/english\/#website\"},\"about\":{\"@id\":\"https:\/\/kojihifu.com\/english\/#clinic-biotope\"},\"reviewedBy\":{\"@id\":\"https:\/\/kojihifu.com\/english\/#physician-karibe\"},\"lastReviewed\":\"2026-09-30\"},{\"@type\":[\"Article\",\"MedicalWebPage\"],\"@id\":\"https:\/\/kojihifu.com\/english\/aga-vs-finasteride-minoxidil-regenerative-tokyo\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kojihifu.com\/english\/aga-vs-finasteride-minoxidil-regenerative-tokyo\/#webpage\"},\"headline\":\"AGA vs Finasteride and Minoxidil: Regenerative Tokyo Guide\",\"url\":\"https:\/\/kojihifu.com\/english\/aga-vs-finasteride-minoxidil-regenerative-tokyo\/\",\"inLanguage\":\"en\",\"author\":{\"@id\":\"https:\/\/kojihifu.com\/english\/#physician-karibe\"},\"reviewedBy\":{\"@id\":\"https:\/\/kojihifu.com\/english\/#physician-karibe\"},\"publisher\":{\"@id\":\"https:\/\/kojihifu.com\/english\/#organization\"},\"mainEntityOfPage\":{\"@id\":\"https:\/\/kojihifu.com\/english\/aga-vs-finasteride-minoxidil-regenerative-tokyo\/#webpage\"},\"description\":\"Compare AGA treatments in Tokyo: finasteride and minoxidil vs PRP and exosome therapy. Explore efficacy data, costs, and book an English-speaking consultation.\",\"datePublished\":\"2026-09-30\",\"dateModified\":\"2026-09-30\",\"lastReviewed\":\"2026-09-30\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kojihifu.com\/english\/aga-vs-finasteride-minoxidil-regenerative-tokyo\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kojihifu.com\/english\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Skin & Dermatology\",\"item\":\"https:\/\/kojihifu.com\/english\/column\/skin-dermatology\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"AGA vs Finasteride and Minoxidil: Regenerative Tokyo Guide\",\"item\":\"https:\/\/kojihifu.com\/english\/aga-vs-finasteride-minoxidil-regenerative-tokyo\/\"}]}]}<\/script><br \/>\n<script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"FAQPage\", \"mainEntity\": [{\"@type\": \"Question\", \"name\": \"Can women use finasteride or dutasteride for AGA in Japan?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"In standard clinical practice, neither oral finasteride nor dutasteride is recommended for women of childbearing age due to the teratogenic risk to a male foetus. Post-menopausal women may be considered for these medications on a case-by-case basis under physician supervision. Oral or topical minoxidil is generally the first-line medication option for women with AGA in Japan, and a consultation is needed to determine what is appropriate for each individual.\"}}, {\"@type\": \"Question\", \"name\": \"How many PRP sessions are required, and when will results appear?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Most protocols involve three to four initial sessions spaced four to six weeks apart, followed by maintenance sessions every four to six months. Clinical data indicate that results are more pronounced at six months than at three months, so patients should allow adequate time before assessing the full response. Early-stage patients with active follicles tend to respond more visibly than those with advanced miniaturisation.\"}}, {\"@type\": \"Question\", \"name\": \"Is it safe to combine regenerative treatments with finasteride or minoxidil?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Yes \u2014 combining standard medications with PRP or exosome therapy is a common and clinically reasonable approach. The medications address the underlying hormonal driver of follicle miniaturisation while regenerative treatments actively stimulate follicle repair and growth. Many patients find that combination treatment delivers stronger outcomes than either modality alone, though individual response varies.\"}}, {\"@type\": \"Question\", \"name\": \"Is exosome therapy safe, and how is it regulated in Japan?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Across 11 clinical studies reviewed in 2025, no serious adverse events were reported with exosome therapy for hair loss \u2014 adverse effects were mild and transient, typically limited to brief scalp redness or swelling. In Japan, the regulatory framework for cell-derived products continues to evolve; exosome therapy is currently available at specialist clinics under physician oversight as an advanced aesthetic treatment rather than under an AGA-specific approved indication. A thorough consultation with a qualified physician is essential before beginning any regenerative programme.\"}}]}<\/script><\/p>\n<h2>What Is Androgenetic Alopecia (AGA)?<\/h2>\n<p><strong>Hair loss<\/strong> can feel discouraging, particularly when it progresses despite consistent treatment. Androgenetic alopecia (AGA) \u2014 commonly called male or female pattern hair loss \u2014 affects an estimated 30 per cent of Japanese men and a significant proportion of women.<\/p>\n<p>Standard medications such as finasteride and minoxidil remain the most widely used interventions, but a growing number of patients ask about regenerative alternatives: treatments that work through the body&#8217;s own repair signals rather than through daily pills or topical applications. This article explains how each approach works, what the evidence currently shows, and what a realistic treatment plan in Tokyo looks like.<\/p>\n<p><strong>What you&#8217;ll learn in this article:<\/strong><\/p>\n<ul>\n<li>How finasteride, dutasteride, and minoxidil work \u2014 and why all AGA treatments are self-pay in Japan<\/li>\n<li>Why some patients explore regenerative alternatives such as PRP and exosome therapy<\/li>\n<li>The clinical evidence for regenerative treatments, including specific efficacy data from recent systematic reviews<\/li>\n<li>A side-by-side comparison of the main AGA treatment options available in Tokyo<\/li>\n<li>How to access English-language AGA consultations in Tokyo<\/li>\n<\/ul>\n<div class=\"kjmc-en-booking-inline\" style=\"background: #f7fbf7; border: 1px solid #d5e6d8; border-radius: 10px; padding: 16px 20px; margin: 26px 0; text-align: center;\">\n<p style=\"margin: 0 0 12px; color: #1a3a1f; font-size: 0.95em; line-height: 1.65;\"><strong>Have a question about this treatment?<\/strong><br \/>\nMessage us on LINE or WhatsApp \u2014 our English-speaking team usually replies the same day.<\/p>\n<p style=\"margin: 0; line-height: 1;\"><a style=\"display: inline-flex; align-items: center; gap: 8px; background: #06C755; color: #fff; padding: 10px 20px; border-radius: 8px; text-decoration: none; font-weight: bold; font-size: 0.92em; margin: 4px 6px; white-space: nowrap; vertical-align: middle;\" href=\"https:\/\/line.me\/R\/ti\/p\/@710uitns?ts=05311801&amp;oat_content=url#~\" target=\"_blank\" rel=\"noopener noreferrer\">Book via LINE<\/a><br \/>\n<a style=\"display: inline-flex; align-items: center; gap: 8px; background: #25D366; color: #fff; padding: 10px 20px; border-radius: 8px; text-decoration: none; font-weight: bold; font-size: 0.92em; margin: 4px 6px; white-space: nowrap; vertical-align: middle;\" href=\"https:\/\/whatsapp.com\/channel\/0029VbCA1v85K3zY4MLX2a1h\" target=\"_blank\" rel=\"noopener noreferrer\">Message on WhatsApp<\/a><\/p>\n<\/div>\n<h2>What Is Androgenetic Alopecia (AGA)?<\/h2>\n<figure style=\"margin: 1.5em 0;\"><img decoding=\"async\" style=\"width: 100%; max-width: 100%; height: auto; border-radius: 8px;\" title=\"AGA vs finasteride and minoxidil: regenerative alt \u2014 What Is Androgenetic Alopecia (AGA)\" src=\"https:\/\/kojihifu.com\/english\/wp-content\/uploads\/2026\/09\/pexels_28994388_1790726277.webp\" alt=\"AGA vs finasteride and minoxidil: regenerative alt \u2014 What Is Androgenetic Alopecia (AGA)\" \/><\/figure>\n<p><strong>Androgenetic alopecia<\/strong> is a genetically influenced, progressive form of hair loss driven by the hormone dihydrotestosterone (DHT). DHT is converted from testosterone by an enzyme called 5-alpha reductase. In individuals with an inherited sensitivity to DHT, the hormone binds to receptors in scalp hair follicles and gradually miniaturises them \u2014 shortening the growth phase and producing progressively finer, shorter hairs until the follicle eventually stops producing visible hair altogether.<\/p>\n<p>In men, AGA typically follows a predictable pattern of frontal recession and crown thinning, classified using the Hamilton\u2013Norwood scale. In women, it more commonly presents as diffuse thinning over the crown with the frontal hairline largely preserved, assessed with the Ludwig scale. The condition is progressive; without intervention, most people experience continued worsening over the years. Early identification and treatment are therefore clinically significant.<\/p>\n<h2>The Standard Medications: Finasteride, Dutasteride, and Minoxidil<\/h2>\n<figure style=\"margin: 1.5em 0;\"><img decoding=\"async\" style=\"width: 100%; max-width: 100%; height: auto; border-radius: 8px;\" title=\"AGA vs finasteride and minoxidil: regenerative alt \u2014 The Standard Medications: Finasteride, Dutasteride, and Mino\" src=\"https:\/\/kojihifu.com\/english\/wp-content\/uploads\/2026\/09\/pexels_7581583_1790726278.webp\" alt=\"AGA vs finasteride and minoxidil: regenerative alt \u2014 The Standard Medications: Finasteride, Dutasteride, and Mino\" \/><\/figure>\n<h3>Finasteride and Dutasteride<\/h3>\n<p><strong>Oral finasteride<\/strong> (1 mg daily) has been approved in Japan since 2005. It works by selectively inhibiting the type II form of 5-alpha reductase, reducing DHT levels in the scalp by approximately 60\u201370 per cent. A large Korean retrospective study cited in a 2025 review in the <em>Annals of Dermatology<\/em> by Shin and Huh found that 85.7 per cent of patients showed improvement compared to their pre-treatment baseline over five years of use.<\/p>\n<p><strong>Oral dutasteride<\/strong> (0.5 mg daily) was approved in Japan for AGA in 2016. Unlike finasteride, it inhibits both type I and type II 5-alpha reductase, producing more complete DHT suppression. The same 2025 review reported that 89.9 per cent of male AGA patients showed improvement at five years with dutasteride \u2014 broadly consistent with it being a modestly stronger agent than finasteride. Both medications are provided on a self-pay basis in Japan; the national health insurance system does not cover AGA treatment, as the condition is classified as cosmetic.<\/p>\n<p>The primary limitation of both agents is that they are maintenance therapies, not cures. If treatment is discontinued, DHT levels return and hair loss typically resumes within twelve months. Sexual dysfunction is a documented side effect of finasteride \u2014 relative risk 1.66 versus placebo per Shin and Huh, 2025 \u2014 though it remains uncommon and resolves in most patients upon stopping the medication. Neither finasteride nor dutasteride is recommended for women who are pregnant or may become pregnant, due to the risk of feminising effects on a male foetus.<\/p>\n<h3>Minoxidil \u2014 Topical and Oral<\/h3>\n<p><strong>Topical minoxidil<\/strong> has been approved in Japan since 1999 in 2 per cent and 5 per cent concentrations. It works primarily as a vasodilator, improving blood flow to the follicle and prolonging the anagen (active growth) phase of the hair cycle. Clinical data suggest that the 5 per cent foam applied once daily is non-inferior to the 2 per cent solution used twice daily (Shin and Huh, 2025), improving day-to-day convenience and adherence.<\/p>\n<p>Low-dose oral minoxidil (typically 2.5 mg daily for men, 1.25 mg for women) has attracted considerable interest as an alternative for patients who find topical application impractical or poorly tolerated, and for women with AGA for whom 5-alpha reductase inhibitors are not appropriate. However, oral minoxidil has not yet received PMDA approval specifically for AGA in Japan; it is available at specialist clinics on a self-pay basis under physician supervision. Side effects at low doses include hypertrichosis \u2014 unwanted body hair growth \u2014 in approximately 10\u201320 per cent of patients, and occasional cardiovascular effects such as fluid retention in susceptible individuals.<\/p>\n<h2>Regenerative Alternatives: PRP, Exosome Therapy, and LLLT<\/h2>\n<figure style=\"margin: 1.5em 0;\"><img decoding=\"async\" style=\"width: 100%; max-width: 100%; height: auto; border-radius: 8px;\" title=\"AGA vs finasteride and minoxidil: regenerative alt \u2014 Regenerative Alternatives: PRP, Exosome Therapy, and LLLT\" src=\"https:\/\/kojihifu.com\/english\/wp-content\/uploads\/2026\/09\/pexels_16131210_1790726279.webp\" alt=\"AGA vs finasteride and minoxidil: regenerative alt \u2014 Regenerative Alternatives: PRP, Exosome Therapy, and LLLT\" \/><\/figure>\n<p><strong>Regenerative treatments<\/strong> for AGA activate or support the follicle&#8217;s own repair mechanisms rather than modifying hormone levels. They are appropriate both as standalone approaches \u2014 especially for patients who cannot or prefer not to take daily medication \u2014 and as adjuncts to finasteride or minoxidil for enhanced outcomes.<\/p>\n<h3>Platelet-Rich Plasma (PRP)<\/h3>\n<p>PRP is prepared by drawing a small volume of the patient&#8217;s own blood and centrifuging it to concentrate the platelets. Platelets are rich in growth factors \u2014 including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and insulin-like growth factor 1 (IGF-1) \u2014 that are released at the injection site to stimulate follicle activity and extend the growth phase. Because PRP uses the patient&#8217;s own blood, it carries minimal risk of allergic or immune reaction.<\/p>\n<p>A 2025 comprehensive review by Gupta et al. in <em>Medical Sciences<\/em> (Basel), analysing 61 PRP studies, found hair density improvements of +23.1 to +49.4 hairs\/cm\u00b2 at six months \u2014 results consistently more pronounced at six months than at three months (+8.1 to +19 hairs\/cm\u00b2). Most protocols involve three to four initial sessions spaced four to six weeks apart, followed by maintenance sessions every four to six months. Outcomes vary with PRP preparation method, platelet concentration, and injection technique, and not all patients respond equally.<\/p>\n<h3>Exosome Therapy<\/h3>\n<p>Exosomes are nanoscale vesicles secreted by cells \u2014 in hair loss treatment, typically derived from mesenchymal stem cells of adipose (fat) tissue or other sources. They carry messenger RNA, microRNA, and signalling proteins that regulate the hair follicle cycle. Because they do not contain living cells, they are distinct from stem cell therapy and carry a simpler handling and safety profile.<\/p>\n<p>A 2025 systematic review by Al Ameer et al. in <em>Clinical, Cosmetic and Investigational Dermatology<\/em>, examining 11 clinical studies including two randomised controlled trials, documented hair density gains of 9.5\u201335 hairs\/cm\u00b2 across different exosome preparations. In a direct comparison reported by Gupta et al. (2025), adipose-derived stem cell (ADSC) exosomes produced a 35 hairs\/cm\u00b2 density improvement compared with 3 hairs\/cm\u00b2 for saline at twelve weeks. Across all reviewed studies, the Al Ameer team noted no serious adverse events and only mild, transient reactions such as temporary scalp redness or swelling. Larger, standardised randomised controlled trials are still needed before definitive regulatory conclusions can be drawn, but the safety profile is consistently reassuring.<\/p>\n<h3>Low-Level Light Therapy and Combination Approaches<\/h3>\n<p>Low-level light therapy (LLLT) uses specific wavelengths of red or near-infrared light to stimulate follicular activity. A Korean randomised study found that 24 weeks of LLLT significantly increased both hair density and hair diameter (Shin and Huh, 2025). Response rates are variable; one large real-world study noted that approximately 70 per cent of patients showed inadequate response to LLLT as a monotherapy, making it better suited as a supportive element of a broader treatment plan than as a primary intervention.<\/p>\n<p>Many patients achieve stronger outcomes by combining standard medication with periodic PRP or exosome treatment \u2014 the medications address the underlying hormonal driver of miniaturisation, while regenerative treatments actively promote follicle repair and growth.<\/p>\n<h2>Comparing AGA Treatment Options at a Glance<\/h2>\n<figure style=\"margin: 1.5em 0;\"><img decoding=\"async\" style=\"width: 100%; max-width: 100%; height: auto; border-radius: 8px;\" title=\"AGA vs finasteride and minoxidil: regenerative alt \u2014 Comparing AGA Treatment Options at a Glance\" src=\"https:\/\/kojihifu.com\/english\/wp-content\/uploads\/2026\/09\/pexels_7469445_1790726280.webp\" alt=\"AGA vs finasteride and minoxidil: regenerative alt \u2014 Comparing AGA Treatment Options at a Glance\" \/><\/figure>\n<table style=\"border-collapse: collapse; width: 100%; margin: 20px 0; font-size: 0.95em; border: 1px solid #ccc;\">\n<thead>\n<tr>\n<th style=\"border: 1px solid #ccc; padding: 10px 12px; background: #f1faf3; text-align: left; font-weight: bold;\">Treatment<\/th>\n<th style=\"border: 1px solid #ccc; padding: 10px 12px; background: #f1faf3; text-align: left; font-weight: bold;\">Mechanism<\/th>\n<th style=\"border: 1px solid #ccc; padding: 10px 12px; background: #f1faf3; text-align: left; font-weight: bold;\">Evidence Level<\/th>\n<th style=\"border: 1px solid #ccc; padding: 10px 12px; background: #f1faf3; text-align: left; font-weight: bold;\">Japan Regulatory Status<\/th>\n<th style=\"border: 1px solid #ccc; padding: 10px 12px; background: #f1faf3; text-align: left; font-weight: bold;\">Key Advantage<\/th>\n<th style=\"border: 1px solid #ccc; padding: 10px 12px; background: #f1faf3; text-align: left; font-weight: bold;\">Key Limitation<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Finasteride 1 mg (oral)<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Reduces DHT via type II 5-alpha reductase inhibition<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Strong \u2014 multiple RCTs, long-term data<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Approved 2005; self-pay for AGA<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">85.7% of patients show improvement at 5 years<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Lifelong use required; sexual side effects; contraindicated in women of childbearing potential<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Dutasteride 0.5 mg (oral)<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Reduces DHT via type I and II inhibition<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Strong \u2014 approved based on RCT data<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Approved 2016; self-pay for AGA<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">89.9% show improvement; modestly stronger than finasteride<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Same cautions as finasteride; generally higher cost<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Topical Minoxidil<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Vasodilation; prolongs anagen phase<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Strong \u2014 OTC; decades of evidence<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Approved 1999; OTC available<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Suitable for men and women; established safety record<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Daily application; scalp irritation possible<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Oral Minoxidil (low dose)<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Systemic vasodilation<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Moderate\u2013Strong \u2014 growing published data<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Not approved for AGA in Japan; self-pay under physician supervision<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Convenient; effective for women; useful when topical is poorly tolerated<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Hypertrichosis in 10\u201320%; cardiovascular monitoring required<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">PRP<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Autologous growth factors stimulate follicles<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Moderate \u2014 61 studies including RCTs<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Not approved for AGA specifically; used under physician oversight<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Drug-free; autologous; +23\u201349 hairs\/cm\u00b2 at 6 months<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Protocol variability; multiple sessions needed<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Exosome Therapy<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Paracrine signalling modulates hair cycle<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Emerging \u2014 11 clinical studies including 2 RCTs<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Not approved for AGA specifically; available at specialist clinics<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">No live cells; 35 hairs\/cm\u00b2 improvement vs. 3 hairs\/cm\u00b2 for saline at 12 weeks<\/td>\n<td style=\"border: 1px solid #ccc; padding: 10px 12px; vertical-align: top;\">Larger standardised trials still needed; higher cost<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Common Misconceptions About AGA Treatment<\/h2>\n<p><strong>Misconception 1: &#8220;Once finasteride restores my hair, I can stop taking it.&#8221;<\/strong><\/p>\n<p>Clinical data consistently show that hair loss resumes \u2014 typically within twelve months \u2014 when finasteride or dutasteride is discontinued. These medications suppress DHT while active in the body; they do not correct the underlying genetic sensitivity of the follicle. The 2025 <em>Annals of Dermatology<\/em> review by Shin and Huh reinforces that the improvements documented at five years are contingent on uninterrupted use. Patients who achieve stable coverage should understand from the outset that this stability depends on continuing treatment.<\/p>\n<p><strong>Misconception 2: &#8220;Regenerative treatments like PRP and exosomes are purely experimental with no real clinical data.&#8221;<\/strong><\/p>\n<p>This understates the current state of the evidence. A 2025 review by Gupta et al. examined 61 PRP studies for AGA and found consistent, measurable improvements in hair density across a wide range of patient populations and preparation protocols. A separate 2025 systematic review by Al Ameer et al. evaluated 11 exosome studies, including two RCTs, documenting density gains of 9.5\u201335 hairs\/cm\u00b2 with no serious adverse events. Neither PRP nor exosome therapy has been formally approved by the PMDA or FDA specifically for AGA, and larger standardised trials are ongoing. &#8220;Emerging, with a substantive and growing evidence base&#8221; is a more accurate characterisation than &#8220;purely experimental.&#8221;<\/p>\n<h2>Cost of AGA Treatment in Tokyo<\/h2>\n<figure style=\"margin: 1.5em 0;\"><img decoding=\"async\" style=\"width: 100%; max-width: 100%; height: auto; border-radius: 8px;\" title=\"AGA vs finasteride and minoxidil: regenerative alt \u2014 Cost of AGA Treatment in Tokyo\" src=\"https:\/\/kojihifu.com\/english\/wp-content\/uploads\/2026\/09\/pexels_28994390_1790726281.webp\" alt=\"AGA vs finasteride and minoxidil: regenerative alt \u2014 Cost of AGA Treatment in Tokyo\" \/><\/figure>\n<p>All AGA treatments in Japan \u2014 including finasteride, dutasteride, topical and oral minoxidil, PRP, and exosome therapy \u2014 are provided on a self-pay basis. The national health insurance system does not cover hair loss treatment because AGA is classified as a cosmetic rather than medical condition.<\/p>\n<p>Medication costs for finasteride and dutasteride vary depending on the clinic and whether branded or generic formulations are dispensed. Procedural treatments such as PRP and exosome therapy are priced per session; clinics frequently offer package pricing for patients committing to a full course. Costs differ between providers and are updated periodically. Please see the clinic&#8217;s official price page or contact us directly for a current quote. For an accurate quote matched to your individual assessment, please book a consultation.<\/p>\n<div class=\"kjmc-en-booking-inline\" style=\"background: #f7fbf7; border: 1px solid #d5e6d8; border-radius: 10px; padding: 16px 20px; margin: 26px 0; text-align: center;\">\n<p style=\"margin: 0 0 12px; color: #1a3a1f; font-size: 0.95em; line-height: 1.65;\"><strong>Have a question about this treatment?<\/strong><br \/>\nMessage us on LINE or WhatsApp \u2014 our English-speaking team usually replies the same day.<\/p>\n<p style=\"margin: 0; line-height: 1;\"><a style=\"display: inline-flex; align-items: center; gap: 8px; background: #06C755; color: #fff; padding: 10px 20px; border-radius: 8px; text-decoration: none; font-weight: bold; font-size: 0.92em; margin: 4px 6px; white-space: nowrap; vertical-align: middle;\" href=\"https:\/\/line.me\/R\/ti\/p\/@710uitns?ts=05311801&amp;oat_content=url#~\" target=\"_blank\" rel=\"noopener noreferrer\">Book via LINE<\/a><br \/>\n<a style=\"display: inline-flex; align-items: center; gap: 8px; background: #25D366; color: #fff; padding: 10px 20px; border-radius: 8px; text-decoration: none; font-weight: bold; font-size: 0.92em; margin: 4px 6px; white-space: nowrap; vertical-align: middle;\" href=\"https:\/\/whatsapp.com\/channel\/0029VbCA1v85K3zY4MLX2a1h\" target=\"_blank\" rel=\"noopener noreferrer\">Message on WhatsApp<\/a><\/p>\n<\/div>\n<h2>Who Is a Good Candidate?<\/h2>\n<p>Standard oral medications \u2014 finasteride, dutasteride, and minoxidil \u2014 are generally appropriate for men and women experiencing active, progressive hair loss who are willing to commit to long-term daily treatment. Men in the early to moderate stages of AGA (Hamilton\u2013Norwood I to V) typically respond most reliably to 5-alpha reductase inhibitors. Women with AGA who are not pregnant and not planning pregnancy may use topical or oral minoxidil; dutasteride and finasteride are not routinely prescribed to women of childbearing potential.<\/p>\n<p>Regenerative treatments are particularly worth exploring for patients who cannot take or prefer to avoid daily oral medication; for those who want to augment an existing medication regimen; and for patients at an early stage of thinning who wish to adopt a proactive, drug-free preventive approach. Both PRP and exosome therapy require that some follicular activity is still present \u2014 these treatments support and stimulate existing follicles and are not a substitute for hair transplantation in areas of complete baldness.<\/p>\n<p>At BIOTOPE CLINIC in Shirokanedai, the initial AGA consultation includes scalp photography and, where appropriate, trichoscopy to document the stage of follicle miniaturisation and to build a personalised treatment plan \u2014 whether that means medication, regenerative treatment, or a structured combination programme.<\/p>\n<h2>Frequently Asked Questions<\/h2>\n<dl class=\"kj-faq\">\n<dt>Q. Can women use finasteride or dutasteride for AGA in Japan?<\/dt>\n<dd>In standard clinical practice, neither oral finasteride nor dutasteride is recommended for women of childbearing age due to the teratogenic risk to a male foetus. Post-menopausal women may be considered for these medications on a case-by-case basis under physician supervision. Oral or topical minoxidil is generally the first-line medication option for women with AGA in Japan, and a consultation is needed to determine what is appropriate for each individual.<\/dd>\n<dd>]<\/dd>\n<dt>Q. How many PRP sessions are required, and when will results appear?<\/dt>\n<dd>Most protocols involve three to four initial sessions spaced four to six weeks apart, followed by maintenance sessions every four to six months. Clinical data indicate that results are more pronounced at six months than at three months, so patients should allow adequate time before assessing the full response. Early-stage patients with active follicles tend to respond more visibly than those with advanced miniaturisation.<\/dd>\n<dd><\/dd>\n<dt>Q. Is it safe to combine regenerative treatments with finasteride or minoxidil?<\/dt>\n<dd>Yes \u2014 combining standard medications with PRP or exosome therapy is a common and clinically reasonable approach. The medications address the underlying hormonal driver of follicle miniaturisation while regenerative treatments actively stimulate follicle repair and growth. Many patients find that combination treatment delivers stronger outcomes than either modality alone, though individual response varies.<\/dd>\n<dd><\/dd>\n<dt>Q. Is exosome therapy safe, and how is it regulated in Japan?<\/dt>\n<dd>Across 11 clinical studies reviewed in 2025, no serious adverse events were reported with exosome therapy for hair loss \u2014 adverse effects were mild and transient, typically limited to brief scalp redness or swelling. In Japan, the regulatory framework for cell-derived products continues to evolve; exosome therapy is currently available at specialist clinics under physician oversight as an advanced aesthetic treatment rather than under an AGA-specific approved indication. A thorough consultation with a qualified physician is essential before beginning any regenerative programme.<\/dd>\n<\/dl>\n<div class=\"kjmc-en-booking-inline\" style=\"background: #f7fbf7; border: 1px solid #d5e6d8; border-radius: 10px; padding: 16px 20px; margin: 26px 0; text-align: center;\">\n<p style=\"margin: 0 0 12px; color: #1a3a1f; font-size: 0.95em; line-height: 1.65;\"><strong>Have a question about this treatment?<\/strong><br \/>\nMessage us on LINE or WhatsApp \u2014 our English-speaking team usually replies the same day.<\/p>\n<p style=\"margin: 0; line-height: 1;\"><a style=\"display: inline-flex; align-items: center; gap: 8px; background: #06C755; color: #fff; padding: 10px 20px; border-radius: 8px; text-decoration: none; font-weight: bold; font-size: 0.92em; margin: 4px 6px; white-space: nowrap; vertical-align: middle;\" href=\"https:\/\/line.me\/R\/ti\/p\/@710uitns?ts=05311801&amp;oat_content=url#~\" target=\"_blank\" rel=\"noopener noreferrer\">Book via LINE<\/a><br \/>\n<a style=\"display: inline-flex; align-items: center; gap: 8px; background: #25D366; color: #fff; padding: 10px 20px; border-radius: 8px; text-decoration: none; font-weight: bold; font-size: 0.92em; margin: 4px 6px; white-space: nowrap; vertical-align: middle;\" href=\"https:\/\/whatsapp.com\/channel\/0029VbCA1v85K3zY4MLX2a1h\" target=\"_blank\" rel=\"noopener noreferrer\">Message on WhatsApp<\/a><\/p>\n<\/div>\n<h2>Where to Get AGA Treatment in Tokyo<\/h2>\n<p>Within our clinic group, both <strong>BIOTOPE CLINIC<\/strong> (Shirokanedai, Minato-ku) and <strong>Kojimachi Dermatology &amp; Plastic Surgery Clinic<\/strong> (Ichigaya, Chiyoda-ku) offer English-language consultation with Dr. Jun Karibe&#8217;s team. AGA treatment \u2014 including finasteride, dutasteride, topical and oral minoxidil, PRP, and exosome therapy \u2014 is handled at <strong>BIOTOPE CLINIC in Shirokanedai<\/strong>, which is the group&#8217;s dedicated centre for men&#8217;s health and cosmetic dermatology. Bookings and enquiries in English are available via LINE or WhatsApp.<\/p>\n<p>Kojimachi Dermatology &amp; Plastic Surgery Clinic in Ichigaya is the group&#8217;s main clinical office, focusing on insurance-covered general dermatology \u2014 eczema, acne, rashes, and related conditions \u2014 as well as general plastic and aesthetic surgery. Both sites are staffed by the same physician-led team and both conduct consultations in English, so patients can choose the location most convenient for them.<\/p>\n<p>If you have questions about AGA treatment, both <strong>BIOTOPE CLINIC<\/strong> (Shirokanedai, Minato-ku) and Kojimachi Dermatology &amp; Plastic Surgery Clinic (Ichigaya, Chiyoda-ku) offer English-language consultation with Dr. Karibe and his team. AGA and men&#8217;s health are primarily handled at BIOTOPE CLINIC in Shirokanedai. English enquiries: LINE or WhatsApp.<\/p>\n<div class=\"kjmc-en-booking-box\" style=\"background: linear-gradient(135deg,#f1faf3 0%,#e6f3ea 100%); border-radius: 14px; padding: 32px 24px; margin: 36px 0 24px; border: 1px solid #c5dccd; text-align: center;\">\n<h3 style=\"margin: 0 0 8px; color: #3a6e3a; border: none; padding: 0; font-size: 1.3em;\">24\/7 Consultation &amp; Booking<\/h3>\n<div style=\"width: 48px; height: 2px; background: #3a6e3a; margin: 0 auto 22px;\"><\/div>\n<p style=\"margin: 0 0 12px; color: #1a3a1f; font-size: 1.1em; font-weight: bold;\">Book a Consultation or Treatment<\/p>\n<p style=\"margin: 0 0 24px; color: #2c4a35; line-height: 1.75;\">Our English-speaking team responds via LINE or WhatsApp \u2014 usually the same day.<\/p>\n<p style=\"margin: 0 0 10px; line-height: 1;\"><a style=\"display: inline-flex; align-items: center; justify-content: center; gap: 10px; background: #06C755; color: #fff; padding: 14px 32px; border-radius: 10px; text-decoration: none; font-weight: bold; font-size: 1.02em; box-shadow: 0 2px 8px rgba(6,199,85,0.25); min-width: 240px; white-space: nowrap;\" href=\"https:\/\/line.me\/R\/ti\/p\/@710uitns?ts=05311801&amp;oat_content=url#~\" target=\"_blank\" rel=\"noopener noreferrer\">Book via LINE<\/a><\/p>\n<p style=\"margin: 0; line-height: 1;\"><a style=\"display: inline-flex; align-items: center; justify-content: center; gap: 10px; background: #25D366; color: #fff; padding: 14px 32px; border-radius: 10px; text-decoration: none; font-weight: bold; font-size: 1.02em; box-shadow: 0 2px 8px rgba(37,211,102,0.25); min-width: 240px; white-space: nowrap;\" href=\"https:\/\/whatsapp.com\/channel\/0029VbCA1v85K3zY4MLX2a1h\" target=\"_blank\" rel=\"noopener noreferrer\">Message on WhatsApp<\/a><\/p>\n<\/div>\n<h2>References<\/h2>\n<ol>\n<li>Shin JW, Huh CH. Updates in Treatment for Androgenetic Alopecia. Annals of Dermatology. 2025;37(6).<\/li>\n<li>Gupta AK, Wang T, Welter R, Unger R, Mejia R. Promises and Pitfalls of Regenerative Therapies for Androgenetic Alopecia: Platelet-Rich Plasma, Photobiomodulation, Stem Cells, and Exosomes. Medical Sciences (Basel). 2025.<\/li>\n<li>Al Ameer MA, Alnajim AT, Al Ameer A, et al. Exosomes and Hair Regeneration: A Systematic Review of Clinical Evidence Across Alopecia Types and Exosome Sources. Clinical, Cosmetic and Investigational Dermatology. 2025.<\/li>\n<\/ol>\n<h2>Related Articles<\/h2>\n<p>You may also find these articles useful.<\/p>\n<ul>\n<li><a href=\"https:\/\/kojihifu.com\/english\/exosome-hair-therapy-tokyo\/\" target=\"_blank\" rel=\"noopener\">Exosome Hair Therapy in Tokyo vs PRP and Mesotherapy<\/a><\/li>\n<li><a href=\"https:\/\/kojihifu.com\/english\/aga-treatment-6-months-results\/\" target=\"_blank\" rel=\"noopener\">AGA Treatment After 6 Months: Realistic Results in Tokyo<\/a><\/li>\n<li><a href=\"https:\/\/kojihifu.com\/english\/aga-telemedicine-japan-expats\/\" target=\"_blank\" rel=\"noopener\">AGA Telemedicine in Japan for Expats: Options and Limits<\/a><\/li>\n<li><a href=\"https:\/\/kojihifu.com\/english\/bringing-finasteride-to-japan-customs\/\" target=\"_blank\" rel=\"noopener\">Bringing Finasteride to Japan: Customs Rules for Expats<\/a><\/li>\n<li><a href=\"https:\/\/kojihifu.com\/english\/dutasteride-japan-dosage-brands\/\" target=\"_blank\" rel=\"noopener\">Dutasteride 0.5 mg in Japan: Dosage, Brands and Prescribing<\/a><\/li>\n<\/ul>\n<div style=\"margin: 2.5em 0 1em; padding: 1.5em; border: 1px solid #d5d5d5; border-radius: 10px; background: #fafafa; font-size: .9em;\">\n<p style=\"font-size: .72em; font-weight: bold; color: #888; margin: 0 0 1.2em; letter-spacing: .08em;\">SUPERVISED BY<\/p>\n<div style=\"display: flex; align-items: flex-start; gap: 1.2em; flex-wrap: wrap;\">\n<div style=\"flex-shrink: 0; text-align: center; min-width: 110px;\"><img decoding=\"async\" style=\"width: 100px; height: 100px; border-radius: 50%; object-fit: cover; object-position: top center; display: block; margin: 0 auto; border: 3px solid #e0e0e0;\" src=\"https:\/\/kojihifu.com\/hon\/wp-content\/uploads\/2022\/01\/photo-karibejun-400-3_re-300x300.jpg\" alt=\"Dr. Jun Karibe MD \u2014 Board-certified Plastic Surgeon, Director of Kojimachi Dermatology &amp; Plastic Surgery Clinic\" \/><\/p>\n<p style=\"margin: .6em 0 .1em; font-weight: bold; font-size: .95em; color: #222;\">Dr. Jun Karibe<\/p>\n<p style=\"margin: 0 0 .1em; font-size: .75em; color: #999;\">MD<\/p>\n<p style=\"margin: 0; font-size: .75em; color: #555; font-weight: bold;\">Director<\/p>\n<\/div>\n<div style=\"flex: 1; min-width: 200px;\">\n<div style=\"margin-bottom: .75em; background: #fff; border: 1px solid #ebebeb; border-radius: 6px; padding: .7em 1em;\">\n<p style=\"margin: 0 0 .35em; font-size: .78em; font-weight: bold; color: #666; border-bottom: 1px solid #f2f2f2; padding-bottom: .3em;\">Education &amp; Career<\/p>\n<div style=\"font-size: .82em; color: #444; line-height: 1.75;\">\n<div>Juntendo University School of Medicine<\/div>\n<div>Department of Plastic Surgery, University of Tokyo Hospital<\/div>\n<div>Assistant Professor, Plastic &amp; Cosmetic Surgery, Saitama Medical University<\/div>\n<div>Assistant Professor &amp; Chief Resident, Yamanashi University Hospital<\/div>\n<div>2019: Founded Kojimachi Dermatology &amp; Plastic Surgery Clinic (Ichigaya, Tokyo)<\/div>\n<div>2021: Founded BIOTOPE CLINIC Shirokanedai (Minato-ku, Tokyo)<\/div>\n<\/div>\n<\/div>\n<div style=\"margin-bottom: .75em; background: #fff; border: 1px solid #ebebeb; border-radius: 6px; padding: .7em 1em;\">\n<p style=\"margin: 0 0 .35em; font-size: .78em; font-weight: bold; color: #666; border-bottom: 1px solid #f2f2f2; padding-bottom: .3em;\">Certifications<\/p>\n<div style=\"font-size: .82em; color: #444; line-height: 1.75;\">\n<div>Board-certified Plastic Surgeon \u2014 Japan Society of Plastic and Reconstructive Surgery<\/div>\n<div>Specialist \u2014 Japan Society of Anti-Aging Medicine<\/div>\n<div>Certified Industrial Physician \u2014 Japan Medical Association<\/div>\n<div>Allergan VST-certified Injector (Botox &amp; Hyaluronic Acid)<\/div>\n<\/div>\n<\/div>\n<div style=\"background: #fff; border: 1px solid #ebebeb; border-radius: 6px; padding: .7em 1em;\">\n<p style=\"margin: 0 0 .35em; font-size: .78em; font-weight: bold; color: #666; border-bottom: 1px solid #f2f2f2; padding-bottom: .3em;\">Awards<\/p>\n<div style=\"font-size: .82em; color: #444; line-height: 1.75;\">\n<div>Best Presentation Award \u2014 Dept. of Plastic Surgery, University of Tokyo (2016)<\/div>\n<div>Excellence Award \u2014 Japan Society of Plastic and Reconstructive Surgery (2018)<\/div>\n<div>Featured Presentation \u2014 ASPS Annual Scientific Meeting, USA (2018)<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div style=\"margin-top: 1em; padding-top: .75em; border-top: 1px solid #e8e8e8; display: flex; flex-wrap: wrap; align-items: center; gap: .5em;\"><a style=\"display: inline-block; background: #e1306c; color: #fff; padding: .4em .9em; border-radius: 4px; text-decoration: none; font-size: .8em; font-weight: bold;\" href=\"https:\/\/www.instagram.com\/dr.jun_\/\" target=\"_blank\" rel=\"noopener noreferrer\">Instagram<\/a><\/p>\n<div style=\"margin-top: 1em; padding-top: .75em; border-top: 1px dashed #d5d5d5; font-size: .78em; color: #555; line-height: 1.7;\">\n<p style=\"margin: 0 0 .3em; font-size: .72em; font-weight: bold; color: #888; letter-spacing: .08em;\">MEDICAL REVIEW<\/p>\n<div><strong>Jun Karibe, MD<\/strong> \u2014 Board-certified Plastic Surgeon \u2014 Japan Society of Plastic and Reconstructive Surgery<\/div>\n<div>Medical Director, BIOTOPE CLINIC<\/div>\n<div>Last medically reviewed: 2026-09-30<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"Compare AGA treatments in Tokyo: finasteride and minoxidil vs PRP and exosome therapy. Explore efficacy data, costs, and book an English-speaking consultation.","protected":false},"author":4,"featured_media":12627,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20,21],"tags":[442],"class_list":["post-12628","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cosmetic-treatments","category-skin-dermatology","tag-aga"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/kojihifu.com\/english\/wp-json\/wp\/v2\/posts\/12628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kojihifu.com\/english\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kojihifu.com\/english\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kojihifu.com\/english\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/kojihifu.com\/english\/wp-json\/wp\/v2\/comments?post=12628"}],"version-history":[{"count":1,"href":"https:\/\/kojihifu.com\/english\/wp-json\/wp\/v2\/posts\/12628\/revisions"}],"predecessor-version":[{"id":12669,"href":"https:\/\/kojihifu.com\/english\/wp-json\/wp\/v2\/posts\/12628\/revisions\/12669"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kojihifu.com\/english\/wp-json\/wp\/v2\/media\/12627"}],"wp:attachment":[{"href":"https:\/\/kojihifu.com\/english\/wp-json\/wp\/v2\/media?parent=12628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kojihifu.com\/english\/wp-json\/wp\/v2\/categories?post=12628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kojihifu.com\/english\/wp-json\/wp\/v2\/tags?post=12628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}